Stock CYAN CYANOTECH CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cyanotech Corporation

Equities

CYAN

US2324373016

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 10:38:49 2024-04-26 am EDT 		5-day change 1st Jan Change
0.2999 USD -0.20% Intraday chart for Cyanotech Corporation -14.44% -66.30%
Feb. 22 Cyanotech Corporation(NasdaqCM:CYAN) dropped from S&P TMI Index CI
Feb. 19 Cyanotech Corporation(NasdaqCM:CYAN) dropped from NASDAQ Composite Index CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 29.34 18.91 12.21 20.12 20.87 5.501
Enterprise Value (EV) 1 34.95 26.19 22.37 26.9 26.89 15.69
P/E ratio 28.4 x -5.23 x 34.3 x 22 x 9.63 x -1.59 x
Yield - - - - - -
Capitalization / Revenue 0.86 x 0.63 x 0.38 x 0.62 x 0.58 x 0.24 x
EV / Revenue 1.02 x 0.87 x 0.7 x 0.83 x 0.75 x 0.68 x
EV / EBITDA 10.4 x -34.1 x 7.29 x 13.2 x 6.36 x -13.8 x
EV / FCF 166 x 83.6 x 19.9 x 11.7 x 35.3 x -12.4 x
FCF Yield 0.6% 1.2% 5.02% 8.55% 2.84% -8.05%
Price to Book 1.63 x 1.28 x 0.78 x 1.18 x 1.07 x 0.34 x
Nbr of stocks (in thousands) 5,753 5,836 5,929 6,097 6,194 6,272
Reference price 2 5.100 3.240 2.060 3.300 3.370 0.8771
Announcement Date 6/15/18 7/1/19 6/23/20 6/22/21 6/22/22 6/27/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März 2018 2019 2020 2021 2022 2023
Net sales 1 34.12 30.2 31.9 32.34 35.97 23.18
EBITDA 1 3.363 -0.768 3.067 2.032 4.23 -1.135
EBIT 1 1.414 -2.747 1.053 0.194 2.574 -2.83
Operating Margin 4.14% -9.1% 3.3% 0.6% 7.16% -12.21%
Earnings before Tax (EBT) 1 0.915 -3.579 0.396 0.923 2.182 -3.422
Net income 1 1.025 -3.596 0.387 0.92 2.154 -3.44
Net margin 3% -11.91% 1.21% 2.84% 5.99% -14.84%
EPS 2 0.1795 -0.6200 0.0600 0.1500 0.3498 -0.5509
Free Cash Flow 1 0.2109 0.3134 1.122 2.302 0.7628 -1.264
FCF margin 0.62% 1.04% 3.52% 7.12% 2.12% -5.45%
FCF Conversion (EBITDA) 6.27% - 36.6% 113.26% 18.03% -
FCF Conversion (Net income) 20.57% - 290.05% 250.16% 35.41% -
Dividend per Share - - - - - -
Announcement Date 6/15/18 7/1/19 6/23/20 6/22/21 6/22/22 6/27/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 5.62 7.28 10.2 6.78 6.02 10.2
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.67 x -9.479 x 3.312 x 3.339 x 1.422 x -8.981 x
Free Cash Flow 1 0.21 0.31 1.12 2.3 0.76 -1.26
ROE (net income / shareholders' equity) 5.91% -21.8% 2.52% 5.59% 11.8% -19.2%
ROA (Net income/ Total Assets) 3% -5.79% 2.14% 0.39% 5.11% -5.73%
Assets 1 34.14 62.14 18.06 237.8 42.13 60.07
Book Value Per Share 2 3.140 2.540 2.640 2.790 3.140 2.610
Cash Flow per Share 2 0.2300 0.1400 0.4000 0.6200 0.4200 0.1600
Capex 1 1.01 0.43 0.22 0.76 1.27 1.07
Capex / Sales 2.95% 1.43% 0.7% 2.35% 3.53% 4.61%
Announcement Date 6/15/18 7/1/19 6/23/20 6/22/21 6/22/22 6/27/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
CYANOTECH CORPORATION Stock Cyanotech Corporation
-66.30% 2.08M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CYAN Stock
  4. Financials Cyanotech Corporation